EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysis

Daniel Sepúlveda-Crespo iD, Ana Treviño-Nakoura iD, José M Bellón, Amanda Fernández-Rodríguez, Pablo Ryan, Isidoro Martínez, María A Jiménez-Sousa, Salvador Resino iD

Reviews in Medical Virology · 2023-05 · 33 (3)

DOI: 10.1002/rmv.2436 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Reviews in Medical Virology, online erschienen am 22.02.2023. Verfasst von Daniel Sepúlveda-Crespo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. Hauptthemen laut MEDLINE: Hepatitis C Antigens, Hepatitis C. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) core antigen (HCVcAg) assay is an alternative for diagnosing HCV infection in a single step. This meta‐analysis aimed to evaluate the Abbott ARCHITECT HCV Ag assay's diagnostic performance (validity and utility) for diagnosing active hepatitis C. PubMed, EMBASE, Scopus, Web of Science, and Cochrane Library were searched until 10 January 2023. The protocol was registered at the prospective international register of systematic reviews (PROSPERO: CRD42022337191). Abbott ARCHITECT HCV Ag assay was the test for evaluation, and nucleic acid amplification tests with a cut‐off ≤50 IU/mL were the gold standard. Statistical analysis was performed using STATA with the MIDAS module and random‐effects models. The bivariate analysis was conducted on 46 studies (18,116 samples). The pooled sensitivity was 0.96 (95% CI = 0.94–0.97), specificity 0.99 (95% CI = 0.99–1.00), positive likelihood ratio 141.81 (95% CI = 72.39–277.79), and negative likelihood ratio 0.04 (95% CI = 0.03–0.06). The area under the summary receiver operating characteristic curve was 1.00 (95% CI = 0.34–1.00). For active hepatitis C prevalence values of 0.1%–15%, the probability that a positive test was a true positive was 12%–96%, respectively, indicating that a confirmatory test should be necessary, particularly with a prevalence ≤5%. However, the probability that a negative test was a false negative was close to zero, indicating the absence of HCV infection. The validity (accuracy) of the Abbott ARCHITECT HCV Ag assay for screening active HCV infection in serum/plasma samples was excellent. Although the HCVcAg assay showed limited diagnostic utility in low prevalence settings (≤1%), it might help diagnose hepatitis C in high prevalence scenarios (≥5%).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C AntigensHepatitis CHumansSensitivity and SpecificityProspective StudiesRNA, ViralHepacivirus

Stichwörter der Autor:innen

HCV core antigenHCV screeningHCVcAgchronic hepatitis Cdiagnostic performance

Substanzen

Hepatitis C AntigensRNA, Viral

Autor:innen und Institutionen

  • Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Servicio de Medicina Interna, Hospital Universitario Infanta Leonor, Madrid, Spain.

ORCID-Profile: Daniel Sepúlveda-Crespo, Ana Treviño-Nakoura, Salvador Resino

Förderung

  • Instituto de Salud Carlos III
  • Gilead Sciences

Zitieren

APA

Sepúlveda-Crespo, D., Treviño-Nakoura, A., Bellón, J. M., Fernández-Rodríguez, A., Ryan, P., Martínez, I., Jiménez-Sousa, M. A., & Resino, S. (2023). Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysis. Reviews in Medical Virology, 33(3). https://doi.org/10.1002/rmv.2436

Vancouver

Sepúlveda-Crespo D, Treviño-Nakoura A, Bellón JM, Fernández-Rodríguez A, Ryan P, Martínez I, et al. Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysis. Reviews in Medical Virology. 2023;33(3). doi:10.1002/rmv.2436

BibTeX
@article{SeplvedaCrespo2023,
  author = {Sepúlveda-Crespo, Daniel and Treviño-Nakoura, Ana and Bellón, José M and Fernández-Rodríguez, Amanda and Ryan, Pablo and Martínez, Isidoro and Jiménez-Sousa, María A and Resino, Salvador},
  title = {Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysis},
  journal = {Reviews in Medical Virology},
  year = {2023},
  volume = {33},
  number = {3},
  doi = {10.1002/rmv.2436}
}
Kostenlos starten →